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Acetylation of the HIV-1 Tat protein by p300 is important for its
transcriptional activity
Melanie Ott*†, Martina Schnölzer*, Jerry Garnica†, Wolfgang Fischle†,
Stephane Emiliani†, Hans-Richard Rackwitz* and Eric Verdin†
The human immunodeficiency virus 1 (HIV-1) Tat
protein activates transcriptional elongation by
recruiting the positive transcription elongation factor
(pTEFb) complex to the TAR RNA element, which is
located at the 5′ extremity of all viral transcripts [1–3].
Tat also associates in vitro and in vivo with the
transcriptional coactivator p300/CBP [4–6]. This
association has been proposed to recruit the histone
acetyltransferase (HAT) activity of p300 to the
integrated HIV-1 promoter. We have observed that the
purified p300 HAT domain acetylates recombinant Tat
proteins in vitro and that Tat is acetylated in vivo. The
major targets of acetylation by p300 are lysine residues
(Lys50 and Lys51) in the arginine-rich motif (ARM) used
by Tat to bind RNA and for nuclear import. Mutation of
these residues in full-length recombinant Tat blocked
its acetylation in vitro. Furthermore, mutation of these
lysine residues to arginine markedly decreased the
synergistic activation of the HIV promoter by Tat and
p300 or by Tat and cyclin T1. These results demonstrate
that acetylation of Tat by p300/CBP is important for its
transcriptional activation of the HIV promoter. 
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Results and discussion
To examine the synergy between Tat and p300, we con-
ducted transient transfection experiments with Tat and
p300 expression vectors and an HIV long terminal repeat
(LTR) construct driving the luciferase reporter gene. In
the absence of p300, Tat increased transcription of the
HIV promoter up to 42-fold (Figure 1a). In the absence of
Tat, p300 had little effect on transcription (1.6-fold
increase); addition of p300 to Tat caused a major super-
induction of Tat transactivation (up to 256-fold). Similar
results were obtained when an HIV promoter construct
containing mutated binding sites for the transcription
factor NFκB was used (Figure 1b). This result indicated
that superinduction of Tat transactivation by p300 was
dependent on an interaction between p300 and Tat rather
than on the interaction between p300 and NFκB/p65.
Importantly, p300 had little or no effect on the Rous
sarcoma virus promoter, which controlled the expression
of Tat proteins (data not shown).
Because the superinduction mediated by p300 was
restricted to the Tat-activated HIV promoter, we
explored the possibility that Tat itself might be the
target of p300 HAT activity. A recombinant protein cor-
responding to the HAT domain of p300 was expressed in
Escherichia coli as a fusion protein with GST (GST–p300-
HAT) [7] and incubated with two purified natural HIV-1
Tat isoforms of 72 and 101 amino acids (Tat72 and
Tat101, respectively) [8] in the presence of [14C]acetyl-
coenzyme A (acetyl-CoA). Acetylation of both Tat pro-
teins occurred in a dose-dependent manner in response
to increasing amounts of GST–p300-HAT (Figure 2a).
As expected, histones H3 and H4 were strongly acety-
lated by GST–p300-HAT and bovine serum albumin
Figure 1
Synergistic activation of the HIV promoter by Tat and p300. HeLa cells
were cotransfected using lipofectamine (Gibco-BRL) with (a) an
LTR–luciferase reporter construct (LTRWT; 180 ng) or (b) an
LTR–luciferase construct in which the two NFκB-binding sites were
mutated (LTR∆NFκB), and increasing amounts of a Tat-expressing
vector [8] (180 ng total DNA, with 20, 60 or 180 ng of Tat-expressing
vector). Transfections were performed in the presence (closed circles)
or absence (open circles) of a p300-expressing vector [12] (600 ng
CMV-p300 or vector alone). Experiments were performed in duplicate
on 80% confluent cells. Luciferase activity was measured with a
standard luciferase assay 24 h after transfection [8]. The mean ± SEM
of three experiments is shown.
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(BSA) was not acetylated (Figure 2a). These findings
demonstrate that Tat proteins are specific targets for the
HAT activity of p300. 
To confirm that Tat is acetylated in vivo, we transfected an
expression vector encoding Tat101 (FLAG epitope-tagged
at the carboxyl terminus) into human 293 cells. The FLAG
epitope did not interfere with the transactivating activity of
Tat on the HIV promoter (data not shown). The FLAG-
tagged protein could be visualized as a nuclear protein (see
Supplementary material). Metabolic labeling of transfected
cells with 3H-labeled sodium acetate for an hour and subse-
quent immunoprecipitation with the anti-FLAG antibody
(M2 antibody, Kodak) identified a single radiolabeled
protein of ~17 kDa that was absent when the empty vector
was transfected (Figure 2b). The same 17 kDa band was
visualized after immunoprecipitation of 35S-methionine-
labeled cellular extracts with the M2 antibody (Figure 2b).
Western blot analysis of the immunoprecipitated material
with a polyclonal anti-FLAG antiserum (Santa Cruz
Biotechnology) confirmed the identity of this protein as Tat
(data not shown). To rule out acetylation of the added
FLAG epitope, we observed that another Tat fusion
protein tagged at the carboxyl terminus with the T7
epitope (Novagen) was also acetylated in vivo (data not
shown). In addition, peptides corresponding to both the
FLAG and to the T7 epitope were not acetylated in vitro by
GST–p300-HAT (Figure 3b).
To map the precise site of acetylation of Tat by p300, we
used a series of synthetic peptides encompassing each
lysine residue of Tat (Figure 3a). Tat peptides were sub-
jected to in vitro acetylation reactions with GST–p300-
HAT, resolved on Tris-Tricine acrylamide gels and
examined by autoradiography. A single peptide corre-
sponding to amino acids 45–58, encompassing the ARM
region of Tat, was acetylated by p300 in vitro (Figure 3b).
Peptides corresponding to the amino-terminal tails of his-
tones H3 and H4, but not the unrelated T7 or FLAG epi-
topes, were labeled by p300, confirming the specificity of
the assay (Figure 3b).
A mutant peptide in which both lysine residues (Lys50
and Lys51) were replaced with alanines was not acetylated
in vitro (Figure 3c). Similarly, mutation of Lys50 and
Lys51 in full-length recombinant Tat expressed in E. coli
reduced p300-mediated [14C]acetate incorporation by
more than 90%, indicating that Lys50 and Lys51 are the
major target of p300 acetylation in the complete Tat
protein (Figure 3d).
Mass spectrometry analysis after in vitro acetylation of
the ARM peptide (amino acids 45–58) by p300 revealed
the appearance of two new products when the acetylation
reaction was performed in the presence of acetyl-CoA.
One major product with a molecular mass of 1,899 Da
corresponded to the monoacetylated form of the peptide
(42 Da larger than the unacetylated peptide) and a minor
product with a molecular mass of 1,941 Da represented
the diacetylated form of the peptide (+ AcCoA, Figure 3f).
These new products were missing when acetyl-CoA was
omitted from the reaction (– AcCoA, Figure 3f) or when
lysine residues were substituted by alanine residues
(data not shown).
To map the major site of acetylation in monoacetylated
Tat, the ARM peptide was digested with Lys-C, an endo-
proteinase that hydrolyzes peptide bonds specifically at
the carboxylic side of lysine residues. Experiments using
synthetic acetylated peptides (acetylated and unacety-
lated) indicated that acetylation of a lysine residue inter-
fered with its cleavage by Lys-C. Following acetylation of
the ARM peptide, a mass increase of 42 Da (addition of
one acetyl group) was exclusively detected in the amino-
terminal Lys51-specific cleavage fragment, which con-
tained both Lys50 and Lys51 residues (ISYGRKK;
Figure 3g). As we did not detect a shift in molecular mass
in the carboxy-terminal Lys50-specific cleavage fragment
containing the Lys51 residue (KRRQRRRP), we con-
cluded that Lys50 is the predominant site of acetylation.
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Figure 2
Tat is acetylated in vitro and in vivo. (a) Acid-extracted histone proteins
(~1 µg), purified recombinant His6-tagged Tat proteins (1 µg, [8]), or
purified BSA (1 µg, Pharmacia) were incubated in a 20 µl reaction with
increasing amounts of a GST fusion protein (0, 1, 2 and 4 µl dialyzed
protein) corresponding to the catalytic domain of p300 (amino acids
1195–1810) [7] in a sodium citrate buffer pH 6 [13], together with
0.1 µCi [1-14C]acetyl-CoA for 30 min at 37°C. Reaction products were
separated by SDS–PAGE and processed for autoradiography. (b) 293
cells were transfected with a vector expressing the full-length Tat101
protein fused at its carboxyl terminus to the FLAG epitope (IBI-Kodak)
or with the empty vector (control). Experiments were performed in
duplicate in 10 mm dishes on 60–80% confluent cells using 60 µl
lipofectamine for 6 h. Twenty-four hours after transfection, cells were
pulsed for 1 h with [3H]acetate (0.2 mCi/plate, ICN) in complete cell
culture medium or overnight with [35S]methionine/cysteine (0.2 mCi/ml,
NEN) in methionine/cysteine-free medium and 10% dialyzed FCS. Tat
was immunoprecipitated from cellular lysates with an anti-FLAG
antibody (M2, Kodak) and the immunoprecipitated material analyzed by
SDS–PAGE and autoradiography (see Supplementary material). Three
independent [3H]acetate-labeling experiments were performed with
similar results.
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Indeed, analysis by nanospray ion-trap spectrometry of
the ISYGRKK fragment isolated after acetylation revealed
collision-induced ion products corresponding to the pres-
ence of acetylated Lys50 (data not shown). In agreement,
the single mutation of Lys50 to an alanine reduced
[1-14C]acetyl incorporation in response to p300 in vitro by
more than 60%, whereas the acetylation level was not
affected when residue Lys51 was mutated to alanine
(Figure 3e). Importantly, mutation of Tat Lys50 and
Lys51 to alanine prevented the acetylation of Tat in vivo
after metabolic labeling of transfected cells with 3H-
labeled sodium acetate (data not shown).
The arginine-rich motif of Tat has been implicated in
several functionally important activities. These include
binding of Tat to TAR, its target RNA element, nuclear
localization, and protein stability. To investigate the
functional relevance of Tat acetylation, we mutated both
Lys50 and Lys51 to either alanine (Tat-AA) or arginine
(Tat-RR) residues in the full-length Tat open reading
frame. These mutations did not interfere with protein
stability (see Supplementary material). However, indi-
rect immunofluorescence experiments revealed that Tat-
AA exhibited partially defective nuclear import (see
Supplementary material). 
We therefore focused our attention on the Tat-RR mutant,
which conserves the positive charge associated with the
unacetylated lysine residue. This substitution has been
used to assess the role of reversible acetylation in the
amino-terminal tails of histone proteins [9]. Substitution of
lysine residue 50 by arginine in the ARM of Tat does not
affect its affinity for TAR [10] (M.O. and E.V., unpublished
observations). Importantly, the same mutations did not
modify the subcellular localization of the Tat protein (see
Supplementary material). To determine whether acetyla-
tion of Tat by p300 is important for the functional synergy
observed between both proteins, we cotransfected expres-
sion plasmids encoding wild-type Tat (Tat-KK) or Tat-RR
with increasing amounts of a plasmid encoding p300 (200
and 600 ng). Substitution of Lys50 and Lys51 with
arginines severely reduced the ability of Tat to activate the
HIV LTR in synergy with p300 (Figure 4a).
As the molecular mechanism of Tat transactivation of the
HIV LTR is based on its interaction with cyclin T1 and
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Figure 3
Mapping of the Tat acetylation sites to lysine residues 50 and 51.
(a) Tat lysine (K) residues are shown aligned with the Tat protein and
its functional domains. Peptides used to map the acetylation site are
shown with respect to the Tat open reading frame. (b) Synthetic
peptides corresponding to Tat domains, to the amino-terminal tails of
histones H3 and H4 and to the T7 and FLAG epitopes were
incubated with the catalytic domain of p300 in the presence of
[1-14C]acetyl-CoA (AcCoA) as described in Figure 2. Reaction
products were separated by electrophoresis on Tris-Tricine gels
(BioRad) and processed for autoradiography. (c) Peptides
corresponding to the amino terminus of histone H4 and to amino acids
45–58 of Tat (Tat 45–58) or to the same region in which Lys50 and
Lys51 were replaced with alanines (Tat-AA 45–58) were incubated
with the catalytic domain of p300 in the presence of [14C]acetyl-CoA
and analyzed as described in (b). (d) Wild-type recombinant His6–Tat
protein or a mutant in which amino acids 50 and 51 were replaced
with alanines (Quickchange site-directed mutagenesis, Stratagene)
were incubated in the presence of increasing amounts of GST–p300
with [1-14C]acetyl-CoA. Reaction products were separated by
SDS–PAGE and analyzed by autoradiography. (e) Synthetic peptides
corresponding to Tat ARM (amino acids 45–58; KK), or mutants in
which Lys50 (AK), Lys51 (KA) or both Lys50 and Lys51 (AA) were
replaced by alanine were incubated with the catalytic domain of p300
in the presence of [1-14C]acetyl-CoA. Reaction products were
visualized by autoradiography and quantified with a Phosphorimager.
(f) Peptide Tat 45–58 was incubated with p300 in the presence or
absence of acetyl-CoA. Samples were analyzed by MALDI mass
spectrometry on the positive ion mode with delayed extraction on a
Reflex II time-of-flight instrument (Bruker-Daltonik GmbH). (g) Peptide
Tat 45–58 incubated with p300 in the presence or absence of
acetyl-CoA was digested with endoproteinase Lys-C (Roche,
peptide:enzyme ratio 10:1, w/v) in 40 mM ammonium bicarbonate at
37°C for 1 h. Digested samples were analyzed by mass spectrometry
with the thin-film preparation technique [14].
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the recruitment of the pTEFb elongation complex, we
investigated the role of Lys50 and Lys51 in the Tat–cyclin
T1 synergy [1]. Murine cyclin T1 cannot synergize with
Tat to enhance Tat affinity for TAR, resulting in deficient
Tat transactivation in murine cells [11]. As reported, this
defective phenotype was corrected when an expression
vector for human cyclin T1 was cotransfected with a Tat
expression vector and an LTR reporter construct in mouse
NIH3T3 cells (Figure 4b). Mutation of Lys50 and Lys51
to arginines prevented the rescue of Tat activity by
human cyclin T1 in murine cells (Figure 4b). This experi-
ment indicates that the conservation of lysine residues
that can be acetylated in the ARM region of Tat is impor-
tant for its ability to synergize with human cyclin T1 to
activate the HIV promoter.
These experiments describe a newly identified post-trans-
lational modification of the HIV transcriptional activator
Tat with important functional consequences. Indeed,
mutation of the acetylation-targeted lysine residues of Tat
impairs its ability to synergize with p300 or with cyclin T1
to activate the HIV promoter. Future experiments will
examine how acetylation of Tat modulates its ability to
interact with TAR and Tat cofactors and should con-
tribute to an increase in our understanding of the molecu-
lar mechanism of Tat action on the HIV promoter.
Supplementary material
Supplementary material including the effects of mutation on Tat stability
and subcellular localization is available at http://current-biology.com
/supmat/supmatin.htm.
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Figure 4
Acetylation of Lys50 and Lys51 is critical for the synergy between
Tat and its cofactors p300 and cyclinT1. (a) HeLa cells were
cotransfected with 180 ng NFκB-deficient LTR–luciferase reporter
construct, 2 ng full-length Tat101-expressing vector (Tat-KK) [8] or
2 ng of a vector expressing a mutated Tat protein in which Lys50 and
Lys51 were mutated to arginines (Tat-RR) or no Tat (Ctl) in the
presence of 200 or 600 ng of the p300-expressing vector (+ p300)
or the empty vector as a control (– p300) [12]. Transfections were
performed according to the protocol described in Figure 1. One
representative experiment, performed in duplicate, out of four is
shown. (b) NIH3T3 cells were cotransfected with 100 ng of the wild-
type LTR–luciferase reporter construct, 10 ng of the Tat-expressing
vector (Tat-KK) or a vector expressing Tat-RR as described above in
the presence of a vector expressing the human cyclin T1 protein
(+ cyclin) or the empty vector as a control (– cyclin) [1]. Cells were
harvested 24 h after transfection and processed in a standard
luciferase assay [8]. The average ± SEM of three independent
experiments performed in duplicate is shown.
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Supplementary results and discussion
Characterization of mutant Tat proteins
Mutations were introduced in codons for lysine residues
50 and 51 in expression vectors for epitope-tagged Tat
proteins (FLAG at the carboxyl terminus). The wild-type
(Tat-KK) and mutant proteins (Tat-AA and Tat-RR) were
characterized in terms of stability using pulse-chase analy-
sis (Figure S1a) and in terms of subcellular localization
using immunofluorescence microscopy (Figure S1b).
Supplementary material
Figure S1
Characterization of mutant Tat proteins. (a) Pulse–chase analysis.
293 cells were transfected with expression vectors for Tat-KK, Tat-AA
and Tat-RR or empty vector (Ctl). Twenty-four hours after transfection,
cells were starved for 1 h in methionine/cysteine-free medium followed
by overnight incubation in [35S]methionine/[35S]cysteine (0.2 mCi/ml).
Cells were chased for different periods of time (0, 2, 4, 8, 16 or 32 h)
in complete medium. Cellular lysates were prepared in 500 µl lysis
buffer (250 mM NaCl, 0.1% NP-40, 20 mM NaH2PO4, 5 mM EDTA
pH 8, 30 mM sodium pyrophosphate, 10 mM NaF, 10 mM sodium
butyrate), duplicates were pooled, and immunoprecipitations were
performed on 1 mg total protein extract with an anti-FLAG antibody
(M2, Kodak, 10 µg/ml lysate) and 30 µl 50% protein-G–Sepharose
slurry (Pharmacia) for 30 min at 4°C. The immunoprecipitated material
was analyzed by SDS–PAGE and autoradiography. Experiments with
[35S]methionine/cysteine labeling were performed with and without
preincubation of the M2-antibody with 1 µg synthetic FLAG peptide
and were exposed to X-ray film for 48 h. (b) Subcellular localization.
Subconfluent HeLa cells, grown overnight on coverslips, were
transfected with expression vectors for Tat-KK, Tat-AA or Tat-RR (2 ng
DNA/µl) using lipofectamine (Gibco-BRL) according to the protocol
described in Figure 1. After 24 h, cells were fixed with 4%
paraformaldehyde in phosphate buffer for 15 min at room temperature,
permeabilized with ice-cold methanol followed by 0.1% Triton X-100
treatment and blocked with 10% FCS in phosphate buffer. Monoclonal
M2-anti-FLAG antibody (Sigma) was used at a final concentration of
3 µg/ml followed by incubation with Cy3-conjugated goat anti-mouse
IgG (Jackson ImmunoResearch Laboratories) at a concentration of
1:600, both for 30 min at room temperature. During the last 5 min of
the incubation of the secondary antibody, 4′6-diamidino-2-phenylindole
(DAPI, Sigma) was included at a final concentration of 10 mg/ml.
Stained preparations were examined on a Zeiss Axiophot microscope
(100× magnification).
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